Clinical Study
Intravenous Iron Dextran as a Component of Anemia Management in Chronic Kidney Disease: A Report of Safety and Efficacy
Table 3
Parameter comparison at three evaluation points in oral iron group.
| Parameter | Evaluation days | Group means ± SD | value |
| Hb (g/dL) | Baseline versus day 30 | 10.9 ± 1.2 | 11.1 ± 1.3 | 0.0258 | Baseline versus day 60 | 10.9 ± 1.2 | 11.3 ± 1.2 | 0.0003 | Day 30 versus day 60 | 11.1 ± 1.3 | 11.3 ± 1.2 | 0.0458 |
| TSAT% | Baseline versus day 30 | 23.2 ± 5.8 | 24.0 ± 7.3 | 0.3318 | Baseline versus day 60 | 23.2 ± 5.8 | 25.0 ± 8.4 | 0.0401 | Day 30 versus day 60 | 24.0 ± 7.3 | 25.0 ± 8.4 | 0.2889 |
| | Baseline versus day 30 | 216.7 ± 146.0 | 221.9 ± 167.0 | 0.4722 | Ferritin (ng/mL) | Baseline versus day 60 | 216.7 ± 146.0 | 220.2 ± 213.5 | 0.8339 | | Day 30 versus day 60 | 221.9 ± 167.0 | 220.2 ± 213.5 | 0.9215 |
|
|